Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02120807 |
Recruitment Status :
Active, not recruiting
First Posted : April 23, 2014
Last Update Posted : April 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stage IV Lung Adenocarcinoma | Drug: Certolizumab Drug: cisplatin Drug: pemetrexed | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Trial of Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas |
Actual Study Start Date : | April 2014 |
Estimated Primary Completion Date : | April 2021 |
Estimated Study Completion Date : | April 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: certolizumab, cisplatin and pemetrexed
Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
|
Drug: Certolizumab Drug: cisplatin Drug: pemetrexed |
- Maximum tolerated does (MTD) [ Time Frame: 2 years ]A standard 3+3 dose-escalation scheme will be used to test two doses of certolizumab: dose level A (200mg) and dose level B (400mg), in combination with the standard dose of chemotherapy. In addition, two de-escalation doses are planned, if dose level A proves too toxic: dose level C (chemotherapy at 75% of the standard dose + certolizumab 200mg) and dose level D (chemotherapy at 75% of the standard dose + certolizumab 400mg)..The MTD is the highest dose at which ≤ 1/6 patients experiences a DLT. Please see the dose escalation schema for exact dose level details.
- Progression-free survival (PFS) [ Time Frame: 2 years ]Patients will be followed from the first drug administration until disease progression (by RECIST 1.1) or death, whichever comes first. Patients alive who have not progressed by the end of the study time will be censored at the time of the last available follow-up. PFS probability will be estimated using Kaplan-Meier methods.
- Immunohistochemical staining [ Time Frame: 2 years ]Biopsies will be performed pre- and post-treatment in all patients and will undergo immunohistochemical staining of TNF-alpha, CXCL1/2, and S100A8/9. Staining will be scored from 0-4. The difference in IHC score from post-treatment to baseline will be compared between patients who have, at minimum, evidence of stable disease during treatment (CR+PR+SD) and the remaining patients, using non-parametric Wilcoxon signed rank test.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Previously untreated stage IV lung adenocarcinoma confirmed at MSKCC
- Age 18 years or older
- Karnofsky Performance Status ≥ 70
- Patients with locally treated, stable, and/or asymptomatic brain metastases are eligible.
- Adequate bone marrow, liver and renal function, as specified below:
- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
- Hemoglobin ≥ 8 g/dL
- Platelets ≥ 100 x 109/L
- Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)
- AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present
- Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.
- Negative PPD test
- For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
- Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter
- Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors
- Archival tissue (10 Unstained Slides - 5 micron sections) from a core biopsy performed and received within 30 days before signing consent or ability to have a fresh core biopsy performed
- Biopsy cannot be from any cytology or bone specimen
- Biopsy site must be amenable to re-biopsy at the end of the study
- Ability to provide written, informed consent
Exclusion Criteria:
- Hypersensitivity to platinum agents
- Ongoing use of investigational agents or use of investigational agents within the last four weeks
- Prior use of agents for TNF-alpha blockade
- History of rheumatoid arthritis, inflammatory bowel disease, or psoriatic arthritis
- Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher)
- Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush
-
Active tuberculosis or untreated, latent tuberculosis
o If a patient has signs, symptoms, or a history suggestive of active tuberculosis, evaluation by an infectious disease physician will be required and active tuberculosis ruled-out prior to enrollment.
- Acute or chronic Hepatitis B or C infection
- Known HIV infection requiring antiretroviral medications and those with AIDS
- Active herpes zoster infection
- Non-healed infected skin ulcers
- History of myocardial infarction or unstable angina within the past 12 months
- Ongoing use of other immunosuppressive medications, including oral steroids and excluding topical steroids
- Women who are breastfeeding Prior history of other malignancy with the exclusion of localized prostate cancer, non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the breast

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02120807
United States, New Jersey | |
Memorial Sloan Kettering at Basking Ridge | |
Basking Ridge, New Jersey, United States, 07920 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center @ Suffolk | |
Commack, New York, United States, 11725 | |
Memorial Sloan Kettering West Harrison | |
Harrison, New York, United States, 10604 | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 | |
Memorial Sloan Kettering at Mercy Medical Center | |
Rockville Centre, New York, United States | |
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center | |
Sleepy Hollow, New York, United States, 10591 |
Principal Investigator: | Paul Paik | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT02120807 |
Other Study ID Numbers: |
13-063 |
First Posted: | April 23, 2014 Key Record Dates |
Last Update Posted: | April 27, 2020 |
Last Verified: | April 2020 |
Certolizumab Cisplatin Pemetrexed thoracic 13-063 |
Adenocarcinoma Adenocarcinoma of Lung Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Cisplatin |
Pemetrexed Certolizumab Pegol Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |